Written by Keen Meds · Reviewed by Licensed Clinical Providers · March 1, 2026
Key Insight: The Hudson 2022 Lancet individual patient data (IPD) meta-analysis pooled raw data from multiple randomized trials and found testosterone therapy significantly improved sexual function, physical function, and bone mineral density compared to placebo in men with hypogonadism.
When evaluating medical treatments, not all evidence is equal. A single study, even a well-designed one, can produce results that are anomalous, population-specific, or difficult to replicate. The highest tier of clinical evidence is a meta-analysis of randomized controlled trials -- a study that synthesizes data from multiple trials to produce a more precise, more generalizable estimate of a treatment's effects. The Hudson 2022 study, published in The Lancet, takes this further still. It uses individual patient data (IPD) from multiple trials rather than aggregated published statistics -- a methodological distinction that matters enormously for the quality and reliability of the conclusions. This article explains what IPD meta-analysis is, what the Hudson study found, and why it represents the most rigorous evidence available on the benefits and safety of testosterone therapy.
What Is an Individual Patient Data Meta-Analysis?
A standard meta-analysis works with published summary statistics -- the means, standard deviations, odds ratios, and confidence intervals that appear in each trial's published report. These summaries are useful, but they discard information. The actual patient-level data -- the individual before-and-after measurements for each participant -- is not accessible from a published paper.
An individual patient data (IPD) meta-analysis is fundamentally different. Researchers contact the investigators of each eligible trial and request the raw, de-identified patient-level data. They then re-analyze all of that data together, using consistent statistical methods across every trial. This produces a pooled dataset that functions almost like a single very large clinical trial.
The advantages of IPD over aggregate meta-analysis are substantial. Researchers can perform consistent subgroup analyses across all trials -- for example, examining whether benefits differ by age, by baseline testosterone level, or by symptom severity. They can control for confounders in a consistent way. They can verify data quality directly. And they can apply the same outcome definitions across all trials, eliminating inconsistencies in how different research groups defined and measured outcomes.
The IPD approach is considered the gold standard for evidence synthesis. When a Lancet IPD meta-analysis confirms a treatment's efficacy, that represents one of the most credible statements medical research can make about a clinical question.
What the Hudson 2022 Study Found
The Hudson 2022 Lancet IPD meta-analysis covered multiple randomized controlled trials of testosterone therapy in men with hypogonadism. The authors assembled individual patient data from the contributing trials and analyzed outcomes across three primary domains: sexual function, physical function, and bone mineral density.
On sexual function, testosterone therapy produced significant improvements compared to placebo. This was measured using validated instruments including sexual function questionnaires and specific items on libido, erectile function, and overall sexual satisfaction. The benefit was consistent across the contributing trials and reached statistical and clinical significance.
On bone mineral density, testosterone therapy produced significant increases at both lumbar spine and femoral neck -- two critical fracture-risk sites. Bone loss in hypogonadal men is a well-established consequence of testosterone deficiency. The fact that this was confirmed in an IPD analysis across multiple trials strengthens the case for testosterone therapy in men with hypogonadism and low bone density or osteoporosis.
On physical function, improvements were observed in muscle strength and physical performance measures, though the magnitude of benefit in this domain was more modest than in sexual function and bone density. Individual variation was substantial, and the benefit in physical function appeared more pronounced in men with more severe baseline deficiency.
On cardiovascular safety, the IPD analysis found no significant increase in cardiovascular events in the testosterone groups compared to placebo across the contributing trials. This was a critical secondary safety finding. With prior observational studies having raised questions about cardiovascular risk, a meta-analysis of randomized trial data showing no significant cardiovascular risk increase is an important reassurance.
Why This Level of Evidence Matters for Patients
Many of the concerns patients and physicians have had about testosterone therapy stem from older, smaller, or methodologically weaker studies. Some of those studies had inconsistent results partly because of design limitations: small sample sizes, heterogeneous populations, variable outcome definitions, and inadequate statistical power.
The Hudson 2022 IPD meta-analysis addresses these limitations systematically. Because it analyzes patient-level data from multiple randomized trials using consistent methods, its conclusions are not vulnerable to the weaknesses of any single trial. Finding consistent improvements in sexual function and bone density, with no significant cardiovascular risk increase, across this type of analysis substantially elevates confidence in these conclusions.
This is particularly important because sexual dysfunction and bone loss are two of the most clinically meaningful consequences of untreated hypogonadism. Untreated testosterone deficiency is not a benign condition -- it is associated with reduced quality of life, increased fracture risk, metabolic deterioration, and mood impairment. The Hudson IPD meta-analysis confirms that these consequences are modifiable with treatment.
Understanding the Limitations
Every study has limitations, and the Hudson IPD meta-analysis is no exception. The results are limited by the trials that contributed data. If the participating trials all enrolled similar populations -- for example, predominantly older men with moderate-to-severe hypogonadism -- the findings may not generalize perfectly to younger men with mild deficiency, or to men with different underlying causes of low testosterone.
The cardiovascular safety finding, while reassuring, was based on trials not primarily designed to evaluate cardiovascular outcomes. The TRAVERSE trial (2023) was specifically designed for that purpose and subsequently confirmed cardiovascular safety in a much larger RCT. The Hudson 2022 and TRAVERSE findings are complementary: the former provides the broadest evidence on efficacy across multiple trial datasets; the latter provides the definitive cardiovascular safety data from a purpose-built, large-scale RCT.
Frequently Asked Questions
What makes the Lancet Hudson 2022 study different from other testosterone meta-analyses?
The key distinction is that it used individual patient data rather than published summary statistics. IPD meta-analysis allows researchers to re-analyze raw data using consistent methods, perform subgroup analyses, and apply uniform outcome definitions -- producing a more precise and reliable estimate of treatment effects than a standard meta-analysis of published results.
What specific sexual function improvements did testosterone therapy produce in the IPD analysis?
Testosterone therapy produced significant improvements in libido, overall sexual satisfaction, and sexual activity frequency compared to placebo. Erectile function improvements were also documented, though the magnitude was somewhat lower than the effects on libido and sexual satisfaction. Erectile dysfunction has multiple causes, and testosterone deficiency is one correctable contributor.
Did the meta-analysis find any serious safety concerns with testosterone therapy?
No statistically significant increase in cardiovascular events was found across the pooled trial data. Polycythemia (elevated hematocrit) was a consistent, expected side effect that requires monitoring. Prostate-related adverse events were not significantly elevated. The analysis confirmed the known safety profile for testosterone therapy used in appropriately selected and monitored patients.
How does the Hudson IPD meta-analysis fit with the TRAVERSE trial?
They are complementary. The Hudson 2022 IPD analysis synthesizes efficacy and safety data across multiple trials using individual patient data -- a broad evidence base. The TRAVERSE trial (2023) was specifically designed as a large cardiovascular safety RCT and confirmed no significant increase in cardiovascular events. Together, they represent the most comprehensive and credible evidence base on TRT efficacy and safety available.
What This Means for Your Treatment Decisions
The Hudson 2022 Lancet IPD meta-analysis represents the highest tier of evidence synthesis available in medicine. Its confirmation of testosterone therapy's benefits for sexual function and bone density, with no significant cardiovascular risk increase, reflects the current scientific consensus on TRT in hypogonadal men.
Keen Meds connects you with licensed clinical providers for a telehealth evaluation and lab review. If your testosterone is clinically low, you may qualify for Testosterone Spray Rx.
